Skip to content

ONCOZENE® 06-0301-01003-02Recalls & reported problems

Boston Scientific Corporation · Microspheres for Embolization · Class 2 · Implant

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 08714729942009), received between Feb 24, 2021 and Feb 24, 2021 — classified as 1 injury.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Most reported problems

Device problems

  • Adverse Event Without Identified Device or Use Problem1

Patient problems

  • Necrosis1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryFeb 24, 2021Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem

    IT WAS REPORTED NECROSIS OCCURRED. ONCOZENE MICROSPHERES WERE SELECTED TO TREAT HEPATOCELLULAR CARCINOMA (HCC) ON (B)(6) 2020. THERE WERE NO DEVICE PERFORMANCE ISSUES. A FOLLOW-UP CT SCAN ON (B)(6) 2020 SHOWED EXTENSIVE NECROSIS AND INFARCTION TO THE RIGHT LOBE.

    Patient problems: Necrosis

    MAUDE report 11372880 ↗

Other Device, Vascular, for Promoting Embolization devices

All Device, Vascular, for Promoting Embolization devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page